People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Other, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avegant Corp. | — | Other | Series B | $87.2M | $74.0M | 2012 |
| AnPac Bio-Medical Science Co., Ltd. | — | Biotechnology | Seed | $4.7M | $23.1M | 2020 |
Edward Tang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Edward Tang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jeff Hastings | 1 | 4 |
| Chen Li | 1 | 3 |
| Lin Yu | 1 | 2 |
| Ken Hausman | 1 | 2 |
| Richard Kerris | 1 | 2 |
| Allan Evans | 1 | 2 |
| Joerg Tewes | 1 | 1 |
| Allan D Evans | 1 | 1 |
| He Zhitao | 1 | 1 |
| Neil Welch | 1 | 1 |
| Annie Rogaski | 1 | 1 |
| Brian Lin | 1 | 1 |
| Kevin Irwin | 1 | 1 |
| Anshul Agarwal | 1 | 1 |
| Aidong Chen | 1 | 1 |
| Jianhua Shao | 1 | 1 |
| Jinqiu Tang | 1 | 1 |
| Pu Xing | 1 | 1 |
| Chris Chang Yu | 1 | 1 |
| He Yu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.